関連する実験動画
Updated: Jan 9, 2026
01:27
Pulmonary Embolism III: Nursing Management
Published on: June 19, 2025
320
ING2 PHDドメインはヒストンH3ライシン4メチレーションを活性遺伝子抑制にリンクしています
Xiaobing Shi1, Tao Hong, Kay L Walter
1Department of Biological Sciences, Stanford University, Stanford, California 94305, USA.
Nature
|May 27, 2006
まとめ
ヒストンH3ライシン4 (H3K4me3) のトリメチル化により,遺伝子発現を積極的に抑制することができる. ING2タンパク質はH3K4me3と結合し,遺伝子プロモーターの抑制複合体を安定させ,DNA損傷反応と腫瘍抑制に影響を与えます.
科学分野:
- エピジェネティクスと分子生物学
- クロマチンの生物学
- 遺伝子規制 遺伝子規制
背景:
- 核プロセスの動的調節には,共振性クロマチンの改変が含まれています.
- ヒストンH3ライシン4メチル化 (H3K4me) は,ユークロマティック領域と遺伝子発現に関連しています.
- H3K4は,H3K4me3が活性遺伝子と関連付けられ,モノ-,二-,または三メチル化することができる.
研究 の 目的:
- メチル化H3K4.4を結合する新しいエフェクタドメインを特定する.
- H3K4メチル化認識におけるINGファミリータンパク質の役割を調査する.
- 遺伝子抑制とDNA損傷に対する細胞反応におけるH3K4me3の機能を明らかにする.
主な方法:
- メチル化されたH3K4エフェクタドメインの識別と特徴付け.
- ING PHDドメインのH3K4me2およびH3K4me3.3への結合親和性を決定するための生化学分析.
- mSin3a-HDAC1複合体におけるING2の役割と,DNA損傷後の遺伝子発現の分析.
主要な成果:
- ING (成長阻害体) タンパク質のPHDドメインは,H3K4me3とH3K4me2.3に特異的に結合する.
- ING2は,抑圧的な複合体の一部であり,H3K4me3.3への高親和結合を示しています.
- ING2-H3K4me3の相互作用は,DNA損傷後の増殖遺伝子プロモーターの抑制複合体を安定させ,遺伝子抑制につながります.
- ING2による遺伝子毒性侮辱反応の調節は,H3K4me3の相互作用に依存しています.
結論:
- H3K4me3は,活性遺伝子抑制に役割を果たし,その機能に関する以前の概念に挑戦しています.
- INGタンパク質,特にING2は,H3K4me3の新しいリーダとして機能し,活性マークと遺伝子抑制を結びつける.
- H3K4me3とING2を含むこのメカニズムは,腫瘍抑制機能とDNA損傷に対する細胞の反応を理解するのに役立ちます.
関連する概念動画
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction
464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K